Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). 2012

Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Etiler, 06330 Yenimahalle, Ankara, Turkey. banoglu@gazi.edu.tr

Pharmacological suppression of leukotriene biosynthesis by 5-lipoxygenase (5-LO)-activating protein (FLAP) inhibitors is a promising strategy to intervene with inflammatory, allergic and cardiovascular diseases. Virtual screening targeting FLAP based on a combined ligand- and structure-based pharmacophore model led to the identification of 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-benzimidazole (7) as developable candidate. Compound 7 potently suppressed leukotriene formation in intact neutrophils (IC(50)=0.31 μM) but essentially failed to directly inhibit 5-LO suggesting that interaction with FLAP causes inhibition of leukotriene synthesis. For structural optimization, a series of 46 benzimidazole-based derivatives of 7 were synthesized leading to more potent analogues (70-72, 82) with IC(50)=0.12-0.19 μM in intact neutrophils. Together, our results disclose the benzimidazole scaffold bearing an ibuprofen fingerprint as a new chemotype for further development of anti-leukotriene agents.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015289 Leukotrienes A family of biologically active compounds derived from arachidonic acid by oxidative metabolism through the 5-lipoxygenase pathway. They participate in host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation. They have potent actions on many essential organs and systems, including the cardiovascular, pulmonary, and central nervous system as well as the gastrointestinal tract and the immune system. Leukotriene
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
June 2014, British journal of pharmacology,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
August 2023, ACS omega,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
March 2020, Journal of chemical information and modeling,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
June 2018, European journal of medicinal chemistry,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
May 2016, European journal of medicinal chemistry,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
August 2014, Proceedings of the National Academy of Sciences of the United States of America,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
December 2007, Acta crystallographica. Section F, Structural biology and crystallization communications,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
July 1992, Molecular pharmacology,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
February 1992, Molecular pharmacology,
Erden Banoglu, and Burcu Çalişkan, and Susann Luderer, and Gökçen Eren, and Yagmur Özkan, and Wolfram Altenhofen, and Christina Weinigel, and Dagmar Barz, and Jana Gerstmeier, and Carlo Pergola, and Oliver Werz
January 2014, PloS one,
Copied contents to your clipboard!